key: cord-1038337-do2zvesc authors: Cohen, Adam F.; van Gerven, Joop; Burgos, Juan Garcia; de Boer, Anthonius; Foucher, Ron A. M.; Flore, H.; Teitelbaum, Zvi; van Eden, Willem; Webb, Andrew; Cremers, Serge title: COVID‐19 vaccines: the importance of transparency and fact‐based education date: 2020-10-14 journal: Br J Clin Pharmacol DOI: 10.1111/bcp.14581 sha: 4ffedc70140d5dcb1a6fcb274ce8506491009020 doc_id: 1038337 cord_uid: do2zvesc nan been called vaccine development at pandemic speed. 2 If transparency was key for public trust in the 'old normality', it becomes more relevant when confronted with this unprecedented paradigm in vaccine development. Vaccine development is always the establishment of a link between working (a neutralizing antibody response or specific T cell development) and helping (the prevention of a disease in a population base with an acceptable safety profile). Although the standards for benefit and risks are the same as for all medicines, the routes for development and assessment will however be stretched to the limit in view of the public health emergency we are facing. SARS-CoV-2 has already killed more humans than HIV and measles together this year 3,4 and produced economic and societal damage that will cause negative effects for years to come, also for worldwide public health. The enormity of the crisis has also led to an extraordinary effort to find treatments, ranging from immunomodulators, antivirals and hyperimmune serums. These include success to date with dexamethasone 5 and remdesivir, 6 which are now widely used in clinical practice in COVID-19 patients 6 months after discovery of the disease. Preventing disease and community spread via mass vaccination is generally assumed to be the best way out of the crisis and this realization has led to more than 160 1 vaccines being developed in parallel. Several published papers report that some of these vaccines have now been shown to work in preclinical and early phase clinical trials 7-9 with regard to neutralizing antibody formation and protection against induced disease in animals. If confirmed by regulatory assessment, this would, in itself, be a major accomplishment especially as this rapid development process has to be in line with guidelines for vaccine development. [10] [11] [12] Trials to evaluate vaccines' safety and efficacy are ongoing, performed under a level of public scrutiny that is understandably beyond the usual public interest for drug development. This puts severe stress on a system that previously proceeded at a much steadier rate. There have been many voices underlining the importance of only releasing vaccines when they are proven to be effective and safe. However, an important nuance is what is meant by 'safe' and how this is perceived by the public, who often assume that 'safe' implies no side effects at all. The difficulty in conveying messages around vaccines' benefits and risks is a fact, and general statements without qualification or proper explanation do not help. Thus, it is particularly important to increase the public understanding that risks are inherent to all medicines, and that no vaccine is 100% effective in preventing a disease or 100% safe in all vaccinated people; despite that, we need to build public understanding and consensus that the benefits of vaccines are unquestionable when one considers, for example, that they where Guillain Barre is listed in the EU prescribing information as adverse events detected post-marketing, but frequency cannot be estimated from the available post-marketing data. 14 Post-vaccination auto-immune events are plausible as they also occur after infections and Guillain-Barré syndrome has been described after the COVID-19 outbreak in Italy. 15 In addition, demonstration of causality can be a prolonged investigation for extended periods as has been shown for the possible association between the vaccine for H1N1 influenza and narcolepsy in Scandinavian countries in 2009. 16 With this knowledge, the occurrence of a very rare adverse event at this stage, such as of transverse myelitis is not entirely unexpected and cannot be attributed with any confidence to the vaccine; the question is when an adverse event is enough reason to stop enrollment. Interrupting a trial would be warranted if the event could change the risk-benefit balance of the trial for other participants, should it be found to be related to the vaccination. In such a case, it may be necessary to (temporarily) interrupt the trial to analyze the event further, to obtain more certainty about the causality or to introduce additional measures to examine or deal with this possibility, or mitigate its risks in future trial participants. Most adverse events are rapidly understood to be in line with the drug's mechanism of action or to be more likely attributable to chance or to underlying disease or other associated conditions. Incidental cases of adverse events that can also occur spontaneously will rarely lead to unex- Whatever happens, the medical and scientific community will also be required to inform patients and the general public, and the message must be consistent and informed. Good information materials and educational programs for the general public should start as soon as possible. In parallel the scientific community will need to be well informed to be able to maintain the trust that is an essential component of a vaccine that helps by strongly reducing the incidence of disease without serious safety issues rather than works by producing an immune response. Even if a vaccine works and helps it can only be of value when the uptake of the vaccine in the general population is sufficiently high. Many younger people will have a low risk of dying from a COVID-19 infection, of about 1:10,000 to about 1: 100,000 17 and therefore clear, truthful and proactive representation of the possibility of serious complications that may or not be causally related or coincidental is essential. In this context EU regulators are taking a step further in increasing the level of transparency for COVID-19 medicines. In particular for all COVID-19 medicines, the European Medicines Agency (EMA) will publish the full product information with details of the conditions of use once the scientific opinion is adopted, even before the formal marketing authorisation is granted. In addition, the publication of the full EPAR (European Public Assessment Report) will be made available within 3 days of authorisation by the European Commission. Furthermore, all clinical data submitted to EMA in support of applications for COVID-19 medicines, as well as the full risk management plan after assessment by the EMA's scientific committees and the subsequent Commission Decision will be published. However, such scientific and regulatory transparency does not automatically translate to public confidence and a much broader educational effort is necessary. It is with this intention of enhancing transparency around COVID-19 vaccines and on safety on particular, that academics and regulators in Europe call for the following actions to be taken urgently in line with other recent calls for action. 18 We therefore reiterate to all parties, including private companies, regulators and other govern- This program must be established by a task force of regulatory and social scientists, media and educational experts and make use of all modern and traditional communication channels and should be established as a matter of the utmost urgency. Listening to people's concerns will be fundamental to any successful approach, 19 including thorough engagement with the general public, intended recipients of the vaccine, consumers and healthcare professionals in discussions on COVID-19 vaccines. Increased transparency by all parties (academic institutions, regulators, commercial participants and governments) will support and make global research more efficient and allow public scrutiny and independent review by academics, medical and public health authorities. Ultimately every effort to open up data to public scrutiny will attract people to the right sources of information and help increase vaccine science literacy, rather than leaving a void where obscure theories can propagate. In a 2019 paper, describing adverse events after the influenza H1N1 pandemic vaccination, Edwards et al conclude. 16 "..one of the lessons learned from the 2009 pandemic was that there is a need for an internationally coordinated vaccine safety infrastructure so that the safety of pandemic vaccines, which are rapidly deployed in large numbers, can be rapidly evaluated. We know another pandemic is coming, but we do not know when." The challenge of dealing with the medical complications of the current pandemic are not over, but as (academic) clinicians, regulators and scientists we have a duty to inform and teach in addition to care and hopefully prevent as well as cure. There are no competing interests to declare. The push for a COVID-19 vaccine Developing Covid-19 vaccines at pandemic speed WHO. Measles Fact Sheet EMA endorses use of dexamethasone in COVID-19 patients on oxygen or mechanical ventilation. Web page Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques An mRNA vaccine against SARS-CoV-2 -preliminary report Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial Department of Health and Human Services., Food and Drug Administration. Development and Licensure of Vaccines to Prevent COVID-19 Guidance for Industry -FDA Guidance for Industry Guideline on clinical evaluation of vaccines Annex 1 Guidelines on clinical evaluation of vaccines Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Guillain-Barré syndrome associated with SARS-CoV-2 Narcolepsy and pandemic influenza vaccination: what we need to know to be ready for the next pandemic Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Meta-Analysis & Public Policy Implications When will we have a vaccine?" -understanding questions and answers about Covid-19 vaccination The biggest pandemic risk? Viral misinformation